Real-world data show tezepelumab reduced severe asthma exacerbations

A retrospective claims-based study (CROSSROADS-3) examined 321 US patients with severe asthma who initiated tezepelumab between December 2021 and August 2022, comparing outcomes 12 months before and after treatment initiation. The study reported a 58% reduction in annualized asthma exacerbation rate, a decrease in average annual cumulative oral corticosteroid dose from 1,295 mg to 770 mg, and fewer exacerbation-related inpatient, emergency department, and outpatient visits. The authors noted reductions were observed in both biologic-naive and biologic-experienced patients and across multiple clinical subgroups, including those with blood eosinophil counts below 300 cells/uL.

Most relevant for: Patients with severe asthma and frequent exacerbations, including those previously treated with another biologic or with lower blood eosinophil counts.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.